3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
29
Multiple Myeloma
26
Breast Neoplasms
24
Carcinoma, Non-Small-Cell Lung
22
Leukemia, Myeloid, Acute
21
Lymphoma
20
Melanoma
16
Lymphoma, Non-Hodgkin
14
Colorectal Neoplasms
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Ovarian Neoplasms
13
Wilms Tumor
11
Myelodysplastic Syndromes
10
Lung Neoplasms
10
Hodgkin Disease
10
Squamous Cell Carcinoma of Head and Neck
9
Sarcoma
9
Neoplasm Metastasis
9
Fallopian Tube Neoplasms
9
Carcinoma, Renal Cell
9
Burkitt Lymphoma
9
Rhabdomyosarcoma
8
Rhabdoid Tumor
8
Neoplasms
8
Leukemia
8
Hepatoblastoma
8
Glioma
8
Colonic Neoplasms
8
Sarcoma, Ewing
7
Osteosarcoma
7
Interventions
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Biliary Tract Neoplasms
×
30 days
×
Clear all
NCT03875235
2026-05-26
TOPAZ-1
AstraZeneca
Phase 3
Active not recruiting
810 enrolled
24 charts
1 FDA